Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cardiff oncology - CRDF

CRDF

Close Chg Chg %
1.61 -0.03 -1.86%

Closed Market

1.58

-0.03 (1.86%)

Volume: 528.63K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Trade Now

Company Overview: cardiff oncology - CRDF

CRDF Key Data

Open

$1.58

 Day Range

1.55 - 1.60

52 Week Range

1.48 - 4.56

 Market Cap

$108.02M

Shares Outstanding

68.37M

 Public Float

62.24M

Beta

1.42

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.69

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

595.09K

  

CRDF Performance

1 Week
 
 1.94%
 
1 Month
 
 -15.96%
 
3 Months
 
 -40.60%
 
1 Year
 
 -42.55%
 
5 Years
 
 -83.61%
 

CRDF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About cardiff oncology - CRDF

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The firm is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

CRDF At a Glance

Cardiff Oncology, Inc.
11055 Flintkote Avenue
San Diego, California 92121
Phone 1-858-952-7570 Revenue 593.00K
Industry Medical Specialties Net Income -45,851,000.00
Sector Health Technology Employees 31
Fiscal Year-end 12 / 2026
View SEC Filings

CRDF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 316.734
Price to Book Ratio 4.229
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.712
Enterprise Value to Sales 219.817
Total Debt to Enterprise Value 0.006

CRDF Efficiency

Revenue/Employee 19,129.032
Income Per Employee -1,479,064.516
Receivables Turnover 3.258
Total Asset Turnover 0.007

CRDF Liquidity

Current Ratio 3.668
Quick Ratio 3.668
Cash Ratio 3.556

CRDF Profitability

Gross Margin -52.445
Operating Margin -8,256.324
Pretax Margin -7,732.04
Net Margin -7,732.04
Return on Assets -57.647
Return on Equity -71.454
Return on Total Capital -99.202
Return on Invested Capital -70.948

CRDF Capital Structure

Total Debt to Total Equity 1.833
Total Debt to Total Capital 1.80
Total Debt to Total Assets 1.344
Long-Term Debt to Equity 0.225
Long-Term Debt to Total Capital 0.221
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cardiff Oncology - CRDF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
386.00K 488.00K 683.00K 593.00K
Sales Growth
+7.52% +26.42% +39.96% -13.18%
Cost of Goods Sold (COGS) incl D&A
200.00K 398.00K 404.00K 904.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
200.00K 398.00K 404.00K 904.00K
Depreciation
200.00K 398.00K 404.00K 904.00K
Amortization of Intangibles
- - - -
-
COGS Growth
-60.00% +99.00% +1.51% +123.76%
Gross Income
186.00K 90.00K 279.00K (311.00K)
Gross Income Growth
+231.91% -51.61% +210.00% -211.47%
Gross Profit Margin
+48.19% +18.44% +40.85% -52.45%
2022 2023 2024 2025 5-year trend
SG&A Expense
40.09M 45.50M 48.93M 48.65M
Research & Development
27.11M 32.86M 36.85M 35.33M
Other SG&A
12.98M 12.64M 12.08M 13.32M
SGA Growth
+39.61% +13.51% +7.53% -0.57%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(39.90M) (45.41M) (48.65M) (48.96M)
Non Operating Income/Expense
1.20M 3.97M 3.22M 3.11M
Non-Operating Interest Income
1.58M 4.07M 3.26M 3.10M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(38.70M) (41.44M) (45.43M) (45.85M)
Pretax Income Growth
-36.81% -7.07% -9.63% -0.92%
Pretax Margin
-10,026.94% -8,492.01% -6,651.68% -7,732.04%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(38.70M) (41.44M) (45.43M) (45.85M)
Minority Interest Expense
- - - -
-
Net Income
(38.70M) (41.44M) (45.43M) (45.85M)
Net Income Growth
-36.81% -7.07% -9.63% -0.92%
Net Margin Growth
-10,026.94% -8,492.01% -6,651.68% -7,732.04%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(38.70M) (41.44M) (45.43M) (45.85M)
Preferred Dividends
24.00K 24.00K 24.00K 25.00K
Net Income Available to Common
(38.73M) (41.47M) (45.45M) (45.88M)
EPS (Basic)
-0.8883 -0.9281 -0.9539 -0.6864
EPS (Basic) Growth
-22.44% -4.48% -2.78% +28.04%
Basic Shares Outstanding
43.60M 44.68M 47.65M 66.84M
EPS (Diluted)
-0.8883 -0.9281 -0.9539 -0.6864
EPS (Diluted) Growth
-22.44% -4.48% -2.78% +28.04%
Diluted Shares Outstanding
43.60M 44.68M 47.65M 66.84M
EBITDA
(39.70M) (45.01M) (48.25M) (48.06M)
EBITDA Growth
-40.02% -13.38% -7.18% +0.40%
EBITDA Margin
-10,285.49% -9,224.18% -7,063.98% -8,103.88%

Snapshot

Average Recommendation BUY Average Target Price 10.25
Number of Ratings 8 Current Quarters Estimate -0.134
FY Report Date 06 / 2026 Current Year's Estimate -0.589
Last Quarter’s Earnings -0.124 Median PE on CY Estimate N/A
Year Ago Earnings -0.69 Next Fiscal Year Estimate -0.777
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 9 8
Mean Estimate -0.13 -0.14 -0.59 -0.78
High Estimates -0.07 -0.09 -0.37 -0.59
Low Estimate -0.20 -0.21 -0.82 -1.12
Coefficient of Variance -28.52 -28.65 -26.59 -22.17

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 8
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Cardiff Oncology - CRDF

Date Name Shares Transaction Value
Feb 19, 2026 Mani Mohindru Interim CEO; Director 368,766 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Brigitte Lindsay Chief Accounting Officer 1,025,334 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 1, 2025 Gary W. Pace Director 1,330,676 Open market or private purchase of non-derivative security Non-derivative transaction at $2.45 per share 3,260,156.20
Aug 1, 2025 Gary W. Pace Director 1,345,676 Open market or private purchase of non-derivative security Non-derivative transaction at $2.45 per share 3,296,906.20

Cardiff Oncology in the News